The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MDT | +4.97% | +4.49% | +0.88% | +128,874% |
| S&P | +19.89% | +109.18% | +15.89% | +7,081% |
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.
The medical-device giant is positioning its Hugo RAS system to compete with Intuitive Surgical's da Vinci systems.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $8.58B | 8.4% |
| Gross Profit | $5.12B | 8.6% |
| Gross Margin | 59.63% | 0.1% |
| Market Cap | $115.62B | 12.3% |
| Market Cap / Employee | $1.22M | 0.0% |
| Employees | 95K | 0.0% |
| Net Income | $1.05B | -0.1% |
| EBITDA | $2.27B | 11.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.27B | -2.9% |
| Accounts Receivable | $6.26B | 4.2% |
| Inventory | 5.9K | 8.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $26.18B | -0.5% |
| Short Term Debt | $2.43B | 56.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.16% | 0.8% |
| Return On Invested Capital | 5.50% | -0.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $584.00M | 25.3% |
| Operating Free Cash Flow | $1.09B | 10.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 27.65 | 27.41 | 23.26 | 25.66 | -3.08% |
| Price to Book | 2.39 | 2.40 | 2.20 | 2.41 | 12.12% |
| Price to Sales | 3.53 | 3.49 | 3.23 | 3.50 | 11.67% |
| Price to Tangible Book Value | -19.22 | -22.88 | -30.08 | -21.50 | 24.32% |
| Price to Free Cash Flow TTM | 62.21 | 62.30 | 67.90 | 70.28 | 3.25% |
| Enterprise Value to EBITDA | 60.87 | 56.05 | 55.24 | 61.97 | 2.63% |
| Free Cash Flow Yield | 1.6% | 1.6% | 1.5% | 1.4% | -3.15% |
| Return on Equity | 8.6% | 8.4% | 9.5% | 9.7% | 22.73% |
| Total Debt | $28.33B | $26.61B | $29.63B | $28.61B | 2.67% |
Medtronic, Fitbit, Apple, and other tech companies hope to combine wearable technology with data analytics to improve outcomes in important diseases such as diabetes.
The approval of Medtronic's artificial pancreas system ushers in a new era for type 1 diabetes treatment. Plus, a new study includes some surprising revelations regarding medical marijuana.
MDT earnings call for the period ending December 31, 2024.
MDT earnings call for the period ending September 30, 2024.
MDT earnings call for the period ending June 30, 2024.
MDT earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
